Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Colleen Tupper also recently made the following trade(s):
- On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.00, for a total value of $58,470.00.
Collegium Pharmaceutical Stock Up 1.2 %
NASDAQ COLL opened at $29.46 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock’s 50 day moving average is $30.85 and its two-hundred day moving average is $32.96. The company has a market capitalization of $927.58 million, a price-to-earnings ratio of 12.70 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of COLL. New Age Alpha Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $40,000. TD Private Client Wealth LLC raised its position in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV raised its position in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Virtus Fund Advisers LLC raised its position in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the last quarter.
Wall Street Analyst Weigh In
COLL has been the topic of a number of recent analyst reports. Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.60.
View Our Latest Stock Report on Collegium Pharmaceutical
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Further Reading
- Five stocks we like better than Collegium Pharmaceutical
- The Most Important Warren Buffett Stock for Investors: His Own
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Short Selling: How to Short a Stock
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Are Penny Stocks a Good Fit for Your Portfolio?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.